Completed PHASE2 INTERVENTIONAL 2-arm NCT02959658

Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis (FUMAPMS)

Sponsor: Biogen

Conditions Primary Progressive Multiple Sclerosis

Updated 9 times since 2017 Last updated: Dec 22, 2020 Started: Dec 31, 2016 Primary completion: Dec 21, 2019 Completion: Dec 9, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02959658, this PHASE2 trial focuses on Primary Progressive Multiple Sclerosis and remains completed. Sponsored by Biogen, it has been updated 9 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Mar 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2
Mar 2019 — Mar 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 4 earlier versions

Dec 2018 — Mar 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Dec 2018 [monthly]

Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
Rigshospitalet, Denmark

Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark